Table 1.
Baseline characteristics of the study participants
| Characteristics | Overall | Quartiles of the TyG index | P | |||
|---|---|---|---|---|---|---|
| Q1 (< 8.20) | Q2 (8.20–8.53) | Q3 (8.54–8.92) | Q4 (> 8.92) | |||
| No. of patients | 1970 | 502 | 487 | 497 | 484 | |
| Age (y) | 66.46 ± 12.35 | 69.91 ± 12.95 | 67.38 ± 12.33 | 65.29 ± 11.97 | 63.17 ± 12.35 | < 0.001 |
| Male (%) | 1345 (68.27%) | 360 (71.71%) | 339 (69.61%) | 323 (64.99%) | 323 (66.74%) | 0.105 |
| Smoking (%) | 580 (29.44%) | 136 (27.09%) | 160 (32.85%) | 142 (28.57%) | 142 (29.33%) | 0.236 |
| Drinking (%) | 217 (11.01%) | 47 (9.36%) | 60 (12.32%) | 53 (10.66%) | 57 (11.78%) | 0.456 |
| BMI (kg/m2) | 26.75 ± 4.41 | 25.12 ± 4.17 | 26.29 ± 3.81 | 27.16 ± 5.07 | 28.40 ± 3.84 | < 0.001 |
| Hypertension (%) | 1377 (69.90%) | 332 (66.13%) | 343 (70.43%) | 350 (70.42%) | 352 (72.73%) | 0.148 |
| SBP on admission (mmHg) | 134.03 ± 26.16 | 124.17 ± 22.64 | 130.92 ± 22.96 | 137.33 ± 28.12 | 144.01 ± 26.34 | < 0.001 |
| DBP on admission (mmHg) | 79.48 ± 11.37 | 73.33 ± 8.55 | 77.07 ± 9.97 | 79.35 ± 9.79 | 88.43 ± 11.22 | < 0.001 |
| Antihypertensive agents (%) | 1122 (56.95%) | 281 (55.98%) | 280 (57.49%) | 282 (56.74%) | 279 (57.64%) | 0.965 |
| Lipid-lowering agents (%) | 1642 (83.35%) | 393 (78.29%) | 400 (82.13%) | 427 (85.92%) | 422 (87.19%) | 0.001 |
| Antiplatelet agents (%) | 0.110 | |||||
| DAPT | 1257 (63.81%) | 322 (64.14%) | 328 (67.35%) | 299 (60.16%) | 308 (63.64%) | |
| MAPT | 471 (23.91%) | 114 (22.71%) | 99 (20.33%) | 131 (26.39%) | 127 (26.24%) | |
| Anticoagulant agents (%) | 53 (2.69%) | 14 (2.79%) | 17 (3.49%) | 10 (2.01%) | 13 (2.68%) | 0.567 |
| Fasting blood glucose (mM) | 5.08 ± 1.33 | 4.53 ± 0.86 | 4.80 ± 0.73 | 5.15 ± 0.93 | 5.85 ± 2.01 | < 0.001 |
| Total cholesterol (mM) | 4.63 ± 1.10 | 4.12 ± 0.96 | 4.49 ± 0.98 | 4.86 ± 1.09 | 5.08 ± 1.14 | < 0.001 |
| Triglyceride (mM) | 1.57 ± 1.07 | 0.80 ± 0.18 | 1.16 ± 0.19 | 1.54 ± 0.28 | 2.81 ± 1.48 | < 0.001 |
| HDL cholesterol (mM) | 1.08 ± 0.28 | 1.18 ± 0.32 | 1.09 ± 0.25 | 1.06 ± 0.26 | 0.98 ± 0.26 | < 0.001 |
| LDL cholesterol (mM) | 3.05 ± 0.98 | 2.64 ± 0.84 | 3.00 ± 0.89 | 3.32 ± 1.00 | 3.27 ± 1.01 | < 0.001 |
| Uric acid (μM) | 360.72 ± 104.39 | 337.30 ± 100.06 | 351.79 ± 102.91 | 362.50 ± 101.41 | 392.08 ± 105.76 | < 0.001 |
| Stroke or TIA history (%) | 366 (18.58%) | 108 (21.51%) | 97 (19.92%) | 85 (17.10%) | 76 (15.70%) | 0.079 |
| CHD history (%) | 153 (7.77%) | 43 (8.56%) | 43 (8.83%) | 33 (6.64%) | 34 (7.02%) | 0.474 |
| Infarct location (%) | < 0.001 | |||||
| Anterior circulation | 1322 (67.11%) | 367 (73.11%) | 331 (67.97%) | 332 (66.80%) | 292 (60.33%) | |
| Posterior circulation | 648 (32.89%) | 135 (26.89%) | 156 (32.03%) | 165 (33.20%) | 192 (39.67%) | |
| Ischemic stroke recurrence (%) | 115 (5.84%) | 14 (2.79%) | 25 (5.13%) | 34 (6.84%) | 42 (8.68%) | 0.001 |
| CE | 11 (9.56%) | 2 (14.28%) | 3 (12.00%) | 3 (8.82%) | 3 (7.14%) | 0.455 |
| LAA | 25 (21.74%) | 3 (21.42%) | 2 (8.00%) | 11 (32.35%) | 9 (21.43%) | |
| SVO | 79 (68.70%) | 9 (64.28%) | 20 (80.00%) | 20 (58.82%) | 30 (71.43%) | |
TyG triglyceride-glucose, BMI body mass index, SBP systolic blood pression, DBP diastolic blood pressure, DAPT dual antiplatelet therapy, MAPT mono antiplatelet therapy, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, TIA transient ischemic attack, CHD coronary artery disease, CE cardio-embolism, LAA large-artery atherosclerosis, SVD small-vessel occlusion